Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model (WB-SCID)
Autore:
Masuzawa, M; Mochida, N; Amano, T; Fujimura, T; Hamada, Y; Tamauchi, H; Sakurai, Y; Nishiyama, S; Katsuoka, K;
Indirizzi:
Kitasato Univ, Sch Med, Dept Dermatol, Sagamihara, Kanagawa 2288555, JapanKitasato Univ Sagamihara Kanagawa Japan 2288555 , Kanagawa 2288555, Japan Kitasato Univ, Sch Med, Dept Microbiol, Sagamihara, Kanagawa 2288555, Japan Kitasato Univ Sagamihara Kanagawa Japan 2288555 , Kanagawa 2288555, Japan Kitasato Univ, Sch Allied Hlth Sci, Sagamihara, Kanagawa 2288555, Japan Kitasato Univ Sagamihara Kanagawa Japan 2288555 , Kanagawa 2288555, Japan
Titolo Testata:
JOURNAL OF DERMATOLOGICAL SCIENCE
fascicolo: 2, volume: 27, anno: 2001,
pagine: 88 - 94
SICI:
0923-1811(200110)27:2<88:EORIIF>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANGIOSARCOMA; LYMPHOCYTES; CELLS; ESTABLISHMENT; LYSIS;
Keywords:
hemangiosarcoma; rIL-2; LAK; SCID mouse model WB-SCID;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Masuzawa, M Kitasato Univ, Sch Med, Dept Dermatol, Sagamihara, Kanagawa 2288555, Japan Kitasato Univ Sagamihara Kanagawa Japan 2288555 288555, Japan
Citazione:
M. Masuzawa et al., "Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model (WB-SCID)", J DERMA SCI, 27(2), 2001, pp. 88-94

Abstract

We treated the patients with cutaneous hemangiosarcoma with recombinant interleukin-2 (rIL-2) immunotherapy that showed clear therapeutic effects. This immunotherapy is popular for the treatment of hemangiosarcoma in Japan. The purpose of this study is to clarify the clinical effects in an animal experiment. After establishing a SCID mouse model of human hemangiosarcoma WB-SCID, we used this model to investigate anti-tumor effects of rIL-2 and LAK cells. We demonstrated that hemangiosarcoma cells are LAK-sensitive, andLAK cells induced by rIL-2 suppress the growth of hemangiosarcoma. Our results may assure the clinical effects of rIL-2 immunotherapy on hemangiosarcoma. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 12:48:06